{"id":"NCT03901339","sponsor":"Gilead Sciences","briefTitle":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","officialTitle":"Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-08","primaryCompletion":"2023-10-20","completion":"2023-10-20","firstPosted":"2019-04-03","resultsPosted":"2024-10-21","lastUpdate":"2024-10-21"},"enrollment":543,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Breast Cancer"],"interventions":[{"type":"DRUG","name":"Sacituzumab Govitecan-hziy","otherNames":["IMMU-132","GS-0132"]},{"type":"DRUG","name":"Eribulin","otherNames":[]},{"type":"DRUG","name":"Capecitabine","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Vinorelbine","otherNames":[]}],"arms":[{"label":"Sacituzumab Govitecan-hziy","type":"EXPERIMENTAL"},{"label":"Treatment of Physician's Choice (TPC)","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to assess and compare the efficacy and safety of sacituzumab govitecan-hzi versus treatment of physician's choice (TPC) in participants with hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC).","primaryOutcome":{"measure":"Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment","timeFrame":"Up to 42.8 months","effectByArm":[{"arm":"Sacituzumab Govitecan","deltaMin":5.5,"sd":null},{"arm":"Treatment of Physician's Choice (TPC)","deltaMin":4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":5},"locations":{"siteCount":113,"countries":["United States","Belgium","Canada","France","Germany","Italy","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["37633306","36027558","32223649","38748596","38270051","39067902","33093337","32946924"],"seeAlso":["https://www.gileadclinicaltrials.com/study/?id=IMMU-132-09"]},"adverseEventsSummary":{"seriousAny":{"events":74,"n":268},"commonTop":["Neutropenia","Nausea","Diarrhoea","Fatigue","Alopecia"]}}